Abstract

You have accessJournal of UrologyProstate Cancer: Detection & Screening V1 Apr 2016MP39-10 SERUM INSULIN-LIKE GROWTH FACTOR-1 (IGF-1) WAS A VALUABLE BIOMARKER TO PREDICT THE HIGH GRADE PROSTATE CANCER IN FINAL PATHOLOGY IN PATIENTS WHO HAD LOW TO INTERMEDIATE DISEASE ON BIOPSY. Myong Kim, Myungchan Park, Jong Won Kim, Donghyun Lee, Won Hee Park, In Gab Jeong, Cheryn Song, Jun Hyuk Hong, Choung-Soo Kim, Tai Young Ahn, and Hanjong Ahn Myong KimMyong Kim More articles by this author , Myungchan ParkMyungchan Park More articles by this author , Jong Won KimJong Won Kim More articles by this author , Donghyun LeeDonghyun Lee More articles by this author , Won Hee ParkWon Hee Park More articles by this author , In Gab JeongIn Gab Jeong More articles by this author , Cheryn SongCheryn Song More articles by this author , Jun Hyuk HongJun Hyuk Hong More articles by this author , Choung-Soo KimChoung-Soo Kim More articles by this author , Tai Young AhnTai Young Ahn More articles by this author , and Hanjong AhnHanjong Ahn More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.135AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES High level of Insulin-like growth factor-1 (IGF-1) was reported to be positively associated with low grade prostate cancer but not to high grade disease. We evaluated the role of preoperative serum IGF-1 level in predicting high grade disease (Gleason score [GS] ≥ 8) in the prostatectomy specimen in patients with low (GS ≤ 6) or intermediate grade (GS = 7) disease on biopsy. METHODS We analyzed the data from 793 patients who received radical prostatectomy. The serum testosterone, IGF-1, and IGF binding protein-3 (IGFBP-3) level were measured immediately before operation. Multivariate analyses were performed to find out predictive parameters for high grade disease in prostatectomy specimen in patients with low or intermediate disease on prostate biopsy. RESULTS Low, intermediate, and high grade disease on final pathology were observed in 159 (20.1%), 502 (63.3%), and 132 (16.6%) patients. Mean IGF-1 levels of patients with low, intermediate, and high grade disease were 151.7 (± 49.8), 144.1 (± 50.0), and 132.9 (± 46.4) ng/mL (p = 0.006). Patients with low preoperative IGF-1 level tended to have high grade disease on final pathology (OR = 0.680; p = 0.013). Serum IGF-1 level was significantly correlated with age (r = -0.313), diabetes mellitus (r = -0.165), serum testosterone level (r = -0.130), and serum IGFBP-3 level (r = 0.583; all p < 0.05). On multivariate analyses, low serum IGF-l level was an independent predictor for high grade disease on final pathology in patients with biopsy GS ≤ 6 (OR = 5.439; p = 0.016), and GS ≤ 7 (OR = 2.489; p = 0.030) after controlling preoperative variables such as age, PSA, prostate volume, percentage of positive core, clinical T stage, serum testosterone, and serum IGFBP-3 level. CONCLUSIONS Serum IGF-1 was a valuable biomarker to predict the high grade disease in final pathology in patients with low to intermediate disease on biopsy. Especially, low serum IGF-1 level in patient with low grade disease on biopsy portends the high grade disease on final pathology. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e545 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Myong Kim More articles by this author Myungchan Park More articles by this author Jong Won Kim More articles by this author Donghyun Lee More articles by this author Won Hee Park More articles by this author In Gab Jeong More articles by this author Cheryn Song More articles by this author Jun Hyuk Hong More articles by this author Choung-Soo Kim More articles by this author Tai Young Ahn More articles by this author Hanjong Ahn More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call